Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.
- DOI
- 10.1186/s12885-024-12112-0
- Published
- 2024 Mar 25
- Container
- BMC cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12885-024-12112-0,
title = {Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.},
author = {McIlroy G and Lax S and Gaskell C and Jackson A and Rhodes M and Seale T and Fox S and Hopkins L and Okosun J and Barrington SF and Ringshausen I and Ramsay AG and Calaminici M and Linton K and Bishton M},
year = {2024},
journal = {BMC cancer},
doi = {10.1186/s12885-024-12112-0},
url = {https://doi.org/10.1186/s12885-024-12112-0}
}RIS
TY - JOUR TI - Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial. AU - McIlroy G AU - Lax S AU - Gaskell C AU - Jackson A AU - Rhodes M AU - Seale T AU - Fox S AU - Hopkins L AU - Okosun J AU - Barrington SF AU - Ringshausen I AU - Ramsay AG AU - Calaminici M AU - Linton K AU - Bishton M PY - 2024 JO - BMC cancer DO - 10.1186/s12885-024-12112-0 UR - https://doi.org/10.1186/s12885-024-12112-0 ER -
APA
G, M., S, L., C, G., A, J., M, R., T, S., S, F., L, H., J, O., SF, B., I, R., AG, R., M, C., K, L., & M, B. (2024). Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.. BMC cancer. https://doi.org/10.1186/s12885-024-12112-0
Source records
- pubmed · retrieved 2026-09-25T23:06:14.580Z